# US 9,867,775 B2 · Topical pharmaceutical bases for treating inflammatory disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,867,775 B2
- Document ID: US9867775B2
- Status: Granted
- Kind: B2
- Application number: 14/830,945
- Filed: 2015-08-20
- Published: 2016-02-25
- Granted: 2018-01-16
- Earliest claimed: 2014-08-20
- Assignees: Professional Compounding Centers of America
- Applicants: Professional Compounding Centers of America (PCCA)
- Inventors: Daniel Banov
- Web page: https://patentgrep.com/patent/US9867775B2

## CPC

- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 31/015: carbocyclic
- A61K 36/32: Burseraceae (Frankincense family)
- A61K 36/47: Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure refers to topical pharmaceutical bases that possess anti-inflammatory properties. Further, these topical pharmaceutical bases are proposed for treating inflammatory disorders, such as swollen tissues within joints and muscles, and the like. The topical pharmaceutical bases include Amazonian oils and resins, such as pracaxi oil and breu-branco resin. The synergistic effect of pracaxi oil combined with breu-branco resin results in a highly effective anti-inflammatory treatment. Suitable active pharmaceutical ingredients (APIs) can be incorporated to the topical pharmaceutical bases to formulate topical pharmaceutical compositions, which improve anti-inflammatory effects. The synergistic effect provided by the combination of pracaxi oil and breu-branco resin enables lower dosage requirements of the associated APIs when topical pharmaceutical compositions are employed for treating inflammatory disorders.

## Claims

### Claim 1

A transdermal pharmaceutical composition comprising:
about 1% w/w to about 95% w/w pracaxi oil,
a synergistically effective amount of breu-branco resin, and
a pharmaceutically effective amount of at least one active pharmaceutical ingredient.

### Claim 2 (depends on 1)

The transdermal pharmaceutical composition of claim 1, wherein the transdermal pharmaceutical composition comprises about 5% w/w to about 50% w/w breu-branco resin.

### Claim 3 (depends on 2)

The transdermal pharmaceutical composition of claim 2, wherein the transdermal pharmaceutical composition comprises about 10% w/w to about 20% w/w pracaxi oil.

### Claim 4 (depends on 2)

The transdermal pharmaceutical composition of claim 2, wherein the transdermal pharmaceutical composition comprises about 10% w/w breu-branco resin.

### Claim 5 (depends on 3)

The transdermal pharmaceutical composition of claim 3, wherein the transdermal pharmaceutical composition comprises about 10% w/w breu-branco resin.

### Claim 6 (depends on 1)

The transdermal pharmaceutical composition of claim 1, wherein the transdermal pharmaceutical composition further comprises at least one natural component selected from the group consisting of buriti oil, copaiba balsam, bacaba oil, acai oil, ojon oil, andiroba oil, murumuru butter, and tucuma oil.

### Claim 7 (depends on 1)

The transdermal pharmaceutical composition of claim 1, wherein the transdermal pharmaceutical composition further comprises at least one natural component selected from the group consisting of about 1% w/w to about 20% w/w buriti oil, about 1% w/w to about 20% w/w copaiba balsam, about 1% w/w to about 20% w/w bacaba oil, about 1% w/w to about 20% w/w acai oil, about 1% w/w to about 20% w/w ojon oil, about 1% w/w to about 20% w/w andiroba oil, about 1% w/w to about 20% w/w murumuru butter, and about 1% w/w to about 20% w/w tucuma oil.

### Claim 8 (depends on 3)

The transdermal pharmaceutical composition of claim 3, wherein the transdermal pharmaceutical composition further comprises at least one natural component selected from the group consisting of about 1% w/w to about 20% w/w buriti oil, about 1% w/w to about 20% w/w copaiba balsam, about 1% w/w to about 20% w/w bacaba oil, about 1% w/w to about 20% w/w acai oil, about 1% w/w to about 20% w/w ojon oil, about 1% w/w to about 20% w/w andiroba oil, about 1% w/w to about 20% w/w murumuru butter, and about 1% w/w to about 20% w/w tucuma oil.

### Claim 9 (depends on 1)

The transdermal pharmaceutical composition of claim 1, wherein the transdermal pharmaceutical composition further comprises at least one natural component selected from the group consisting of about 5% w/w buriti oil, about 5% w/w copaiba balsam, about 5% w/w bacaba oil, about 5% w/w acai oil, about 5% w/w ojon oil, about 5% w/w andiroba oil, about 5% w/w murumuru butter, and about 5% w/w tucuma oil.

### Claim 10 (depends on 1)

The transdermal pharmaceutical composition of claim 1, wherein the transdermal pharmaceutical composition is selected from the group consisting of a pharmaceutically acceptable liquid, a cream, an oil, a lotion, an ointment, a gel, a roll-on liquid, a skin patch, a spray, and a synthetic polymer dressing.